Our purpose is to reimagine medicine to improve and extend people’s lives.
We use innovative science and technology to address some of society’s most challenging healthcare issues and we work together with the system to implement solutions that drive access for UK patients.
From research to delivery, we are a valued partner in the healthcare ecosystem, supporting in times of crisis and beyond, to build solutions that provide better care and access opportunities for every patient in the UK.
We are in the midst of a silent pandemic; a second healthcare crisis in which millions of people are waiting for NHS treatment. The NHS will need to manage this unprecedented backlog, as well as progress and improve care for the future. This is a challenge that requires bold solutions, close collaboration and exciting innovation.
At Novartis, we are strongly positioned to help the NHS recover. We have a broad portfolio of treatments aligned to the clinical priorities of the NHS and the Long Term Plan; from cancer care to cardiovascular disease.
COVID-19 has taught us that if we are to bring about real change, we must collaborate like never before.
We partner with the NHS and the
entire health ecosystem to identify and implement healthcare solutions for patients most in need, no matter where they are or what their background.
We are also looking ahead to deliver for the patients of tomorrow; we have one of the most exciting pipelines of any company in the industry. Through this, and through digital and data-led solutions identified by the Novartis Biome (our digital innovation lab), we reimagine medicine to change tomorrow and ensure no patient is left behind.
Exact Sciences is a leading, global provider of cancer screening and diagnostic tests. Building on the success of the Oncotype DX® and the Cologuard® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. We serve patients in more than 90 countries and are building an even stronger international business to bring our tests to patients around the world. For more information, visit the company’s website and follow us on Twitter, Facebook or LinkedIn